In This Article:
Raymond James lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $60 from $61 and keeps a Strong Buy rating on the shares. Ionis beat nicely in Q4, and the 2025 floor guidance for revenue and operating loss appears reasonable as Ionis transitions to more of a commercial story, the analyst tells investors in a research note.
Discover the Best Stocks and Maximize Your Portfolio:
-
See what stocks are receiving strong buy ratings from top-rated analysts.
-
Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IONS:
-
Ionis Pharmaceuticals price target lowered to $63 from $65 at BofA
-
Ionis Pharmaceuticals price target lowered to $45 from $60 at BMO Capital
-
Ionis Pharmaceuticals: Hold Rating Amid Revenue Growth, Competitive Pressures, and Delayed Catalysts
-
Ionis Pharmaceuticals: Balancing Strong R&D Revenues with Market Challenges – Hold Rating Justified
-
Ionis Pharmaceuticals price target lowered to $64 from $67 at Citi